SCHEMBL2178347

SCHEMBL2178347

COC(=O)C(C)(C)N1Cc2ccc(Br)cc2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA6 Q16445 1/20 0.36
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
ABHD6 Q9BV23 1/20 0.35
SDCBP O00560 1/20 0.35
SDC2 P34741 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 1/20 0.35
CUL4A Q13619 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HSD17B3 P37058 3/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18765683 0.88 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL18793920 0.81 MEN1 (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2181030 0.80 MAP3K5 (0.42) SDCBPSDC2ALDH1A1MAPK1KDM4E
SCHEMBL23309876 0.80 MEN1 (0.36) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL28359571 0.80 MEN1 (0.36) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL18065186 0.77 SDCBP (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL19475669 0.75 HSD17B3 (0.39) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL16099526 0.73 SDCBP (0.47) KMT2AMEN1ABHD6SDCBPSDC2
SCHEMBL17141692 0.73 PIK3CA (0.46) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2180472 0.73 MAPK1 (0.46) KMT2AMEN1CUL4AALDH1A1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT GABRA1 3653/4885GABRG2 4381/4885GABRB3 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.